A Combination of Avutometinib Plus Defactinib Results in Clinically Meaningful Benefit in Patients with Recurrent Low-Grade Serous Ovarian Cancer By Ogkologos - August 5, 2025 433 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ENGOT-OV60/GOG-3052/RAMP 201 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR Dame Deborah James’ incredible legacy: The Bowelbabe Fund announces first funded... April 5, 2023 Researchers Develop a Potential “Universal” CAR T-Cell Therapy for Blood Cancers September 27, 2023 Groundbreaking Physicist Uses Laser Technology To Kill Cancer Cells Without Any... June 9, 2020 High Frequency of Germline ATM Variants in CLL November 11, 2022 Load more HOT NEWS Benefit in OS with Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant... EMA Recommends Extending the Indications for Dostarlimab Licorice: The Unique Root With 10 Amazing Health Benefits DNA from Ancient Viruses Helps Many Cancers Grow
